Giannis Mountzios: How active ADCs against oncogene-addicted NSCLC?
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, posted on LinkedIn about recent paper he and colleagues co-authored, titled “Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target” published on Science Direct.
Authors: Giannis Mountzios, Stephanie P.L. Saw, Lizza Hendriks, Jessica Menis, Tina Cascone, Oscar Arrieta, Jarushka Naidoo, Prodromos Koutoukoglou, Massimiliano Cani, Antoine Lefevre, Alfredo Addeo, Solange Peters, Jordi Remon
“How active are antibody-dug conjugates (ADCs) against oncogene-addicted NSCLC? Should we use biomarker-selected or biomarker-agnostic ADCs?
Just published in ESMO Treatment Reviews Journal, a comprehensive overview on current landscape, challenges and perspectives
Grateful to co-ordinate and work with a stellar global team, including Stephanie Saw, lizza hendriks, Jessica Menis, Tina Cascone, Oscar Arrieta, Jarushka Naidoo, Alfredo Addeo, Prodromos Koutoukoglou, Peters Solange and senior author Jordi Remon.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023